Our lead pipeline candidate etripamil is a proprietary chemical entity that was conceived, discovered and optimized by Milestone.

Milestone is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the acute treatment of patients with PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.

Etripamil is not currently approved for the treatment of PSVT or for any other indication anywhere in the world.